HER2陽性轉移性乳癌治療新希望－從護理的觀點談賀癌寧（trastuzumab emtansine）及其照護

New Hope for HER2-Positive Metastatic Breast Cancer Treatment: Trastuzumab Emtansine (T-DM1) From the Perspective of Nursing Care

10.6224/JN.63.5.121

郭曉萱(Hsiao-Hsuan Kuo)；陳偉武(Wei-Wu Chen)

乳癌 ； 賀癌寧 ； 血小板減少 ； 肝功能異常 ； 疲憊 ； breast cancer ； trastuzumab emtansine ； thrombocytopenia ； liver dysfunction ； fatigue

護理雜誌

63卷5期（2016 / 10 / 01）

121 - 126

繁體中文

第二型人類上皮細胞生長因子接受器（human epidermal growth factor receptor, HER2）陽性的乳癌病患，具較嚴重的疾病及較差的預後。對抗HER2的標靶藥物－賀癌平（trastuzumab）的發展，使得HER2陽性乳癌的病患存活率顯著提升。然而，轉移性HER2陽性的乳癌最終都將會發展出抗藥性。近年來，新的抗體與化學治療複合（anti body-drug conjugate）的藥物－賀癌寧（trastuzumab emtansine, T-DM1），可以改善抗藥性乳癌的治療成效。賀癌寧可能會出現的副作用有：血小板減少、肝功能指數升高、疲憊、心臟功能的影響、肺炎及周邊神經病變等。護理師必須瞭解此藥物的作用機制及副作用、給藥注意事項、評估副作用及處理方法，以確保病患安全，提升照護能力及護理品質。

Human epidermal growth factor receptor (HER2)-positive breast cancer is associated with a more aggressive disease and poor prognosis. The development of trastuzumab, a HER2-targeted agent, has changed the paradigm of HER2-positive breast cancer treatment and improved survival rates dramatically. However, metastatic HER2-positive breast cancer patients eventually develop resistance to this treatment regimen eventually. A new anti-HER2 antibody-drug conjugate, Trastuzumab emtansine (T-DM1), has been shown to improve treatment efficacy. However, side effects that differ from trastuzumab, including thrombocytopenia, liver dysfunction, fatigue, cardiotoxicity, pneumonitis, and peripheral neuropathy, may occur. Clinical nurses must understand the mechanism of this new agent and be aware of the symptoms and signs related to its side effects. Furthermore, clinical nurses should understand the varying degrees of these side effects, their probable causes, and the potential approaches to their management. Finally, clinical nurses must understand how to administer this agent in order to ensure patient safety. Understanding the side effects of T-DM1 and their management will help elevate nursing quality and caring efficacy.

1. 羅氏（2014）．賀癌寧． 取自http://www.roche.com.tw/content/dam/roche_taiwan/zh_TW/download/Kadcyla.pdf[Roche. (2014). KADCYLA®. Retrieved from http://www.roche.com.tw/content/dam/roche_taiwan/zh_TW/download/Kadcyla.pdf]
2. 衛生福利部統計處（2014）．102 年死因統計結果分析．取自http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=5150 [Department of Statistics, Ministry of Health and Welfare, Taiwan, ROC. (2014). Analysis of cause of death statistics, 2013. Retrieved from http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=5150]
3. Bachelot, T.,Romieu, G.,Campone, M.,Diéras, V.,Cropet, C.,Dalenc, F.,Labbe-Devilliers, C.(2013).Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study.The Lancet Oncology,14(1),64-71.
4. Bender, B. C.,Schaedeli-Stark, F.,Koch, R.,Joshi, A.,Chu, Y. W.,Rugo, H.,Gupta, M.(2012).A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.Cancer Chemotherapy and Pharmacology,70(4),591-601.
5. Borneman, T.(2013).Assessment and management of cancerrelated fatigue.Journal of Hospice & Palliative Nursing,15(2),77-86.
6. Bourdeanu, L.,Luu, T.(2013).Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.Clinical Journal of Oncology Nursing,17(5),E58-E62.
7. Diéras, V.,Harbeck, N.,Budd, G. T.,Greenson, J. K.,Guardino, A. E.,Samant, M.,Krop, I. E.(2014).Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: An integrated safety analysis.Journal of Clinical Oncology,32(25),2750-2757.
8. Geyer, C. E.,Forster, J.,Lindquist, D.,Chan, S.,Romieu, C. G.,Pienkowski, T.,Cameron, D.(2006).Lapatinib plus capecitabine for HER2-positive advanced breast cancer.The New England Journal of Medicine,355(26),2733-2743.
9. Kirshbau, M.(2010).Cancer-related fatigue: A review of nurisng interventions.British Journal of Community Nursing,15(5),214-219.
10. Krop, I. E.,Kim, S. B.,Ganzález-Martin, A.,LoRusso, P. M.,Ferrero, J. M.,Smitt, M.,Wildiers, H.(2014).Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomized, open-label, phase 3 trial.The Lancet Oncology,15(7),689-699.
11. Oostra, D. R.,Macrae, E. R.(2014).Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.Breast Cancer: Targets and Therapy,6,103-113.
12. Peddi, P. F.,Hurvitz, S. A.(2014).Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptors 2 (HER2)-positive metastatic breast cancer: Latest evidence and clinical potential.Therapeutic Advances in Medical Oncology,6(5),202-209.
13. Radovich, P.(2011).The multiple causes and myriad presentations of thrombocytopenia.American Nurse Today,6(1),9-12.
14. Smith, N. Z.(2012).Treating metastatic breast cancer with systemic chemotherapies: Current trends and future perspectives.Clinical Journal of Oncology Nursing,16(2),E33-E43.
15. Swain, S. M.,Kim, S. B.,Cortés, J.,Ro, J.,Semiglazov, V.,Campone, M.,Baselga, J.(2013).Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomized, double-blind, placebo-controlled phase 3 study.The Lancet Oncology,14(6),464-471.
16. Uppal, H.,Doudement, E.,Mahapatra, K.,Darbonne, W. C.,Bumbaca, D.,Shen, B. Q.,Ramakrishnan, V.(2015).Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).Clinical Cancer Research,21(1),123-133.
17. Verma, S.,Miles, D.,Gianni, L.,Krop, I. E.,Welslau, M.,Baselga, J.,Blackwell, K.(2012).Trastuzumab emtansine for HER2-positive advanced breast cancer.The New England Journal of Medicine,367(19),1783-1791.
18. Winkeljohn, D.(2013).Diagnosis, treatment, and management of immune thrombocytopenia.Clinical Journal of Oncology Nursing,17(6),664-666.
19. Wolff, A. C.,Hammond, M. E. H.,Hicks, D. G.,Dowsett, M.,McShane, L. M.,Allison, K. H.,Hayes, D. F.(2013).Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update.Journal of Clinical Oncology,13(31),3997-4013.
20. Yan, H.,Endo, Y.,Shen, Y.,Rotstein, D.,Dokmanovic, M.,Mohan, N.,Wu, W. J.(2016).Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity.Molecular Cancer Therapeutics,15(3),480-490.
21. 姜紹青(2014)。Ado-trastuzumab emtansine：第一個用於固態腫瘤之抗體結合藥品。腫瘤護理雜誌，14(2)，19-26。
22. 盧彥伸(2013)。乳癌的標靶治療。台灣醫學，17(4)，412-419。

1. 張滋娉,馬秀玲,李月麗(2019)。一位初診斷乳癌病患接受先導性化學治療併標靶治療之護理經驗。腫瘤護理雜誌，19(增訂刊)，123-135。